Remove Branding Remove Containment Remove Generic Drugs Remove Licensing
article thumbnail

Buscopan vs Mebeverine | OTC IBS treatment

Druggist

(video) Buscopan vs Mebeverine: mechanism of action and symptoms control Although used in the symptomatic treatment of the same condition, Buscopan and mebeverine are not the same drugs. Buscopan is a brand name for a drug called hyoscine butylbromide. Each Colofac or mebeverine tablet contains 135mg of mebeverine hydrochloride.

article thumbnail

Lymecycline for ACNE: Questions & Answers

Druggist

Lymecycline is usually prescribed as a generic drug – lymecycline 408mg capsules or occasionally as a branded medication called Tetralysal 300 mg capsules. Both drugs are the same medicines. Although licensed for acne, minocycline is rarely prescribed in the UK. How does lymecycline work for acne?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Cerelle vs Cerazette: Are they really the same?

Druggist

Cerelle and Cerazette are two brands of daily progestogen-only pill (POP), also known as mini-pill. In recent years prescribing of Cerazette in NHS decreased, in place of other brands, including Cerelle. Do generic, and branded drugs produce exactly the same effect? . How can I get Cerazette pill? Cerazette**.

article thumbnail

Truvada for PrEP: availability, cost and side effects

Druggist

Truvada (emtricitabine/tenofovir disoproxil) is an antiviral drug used in the treatment of HIV, alone or as part of antiviral combination therapy. Truvada is also licensed as pre-exposure prophylaxis (PrEP) medication. One important message to take away is that Truvada and equivalent generic drugs are not 100% effective.

article thumbnail

PFIZER REPORTS STRONG FIRST-QUARTER 2021 RESULTS

The Pharma Data

Panzyga (immune globulin intravenous [human] ifas 10% liquid preparation) — In February 2021, Pfizer announced that the FDA approved the supplemental Biologics License Application (sBLA) for Panzyga to treat adult patients with a rare neurological disease of the peripheral nerves called chronic inflammatory demyelinating polyneuropathy (CIDP).

article thumbnail

Exforge antitrust settlement caps Novartis’ year of legal disputes

Pharmaceutical Technology

In 2020, the Federal Trade Commission issued a report regarding settlements reached between brand and generic manufacturers in FY 2017 and noted that “for the first time since [FY] 2004, no settlement agreement in [FY] 2017 contains a no-[authorized generic] AG commitment.”. Gilenya legal drama.

Doctors 242